利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

127 条记录 (耗时 0.029 秒)

    NANOGELS FOR DELAYED GELATION
    62.
    发明申请
    NANOGELS FOR DELAYED GELATION 有权
    延迟凝胶的纳米胶

    公开(公告)号：US20140202693A1

    公开(公告)日：2014-07-24

    申请号：US14143169

    申请日：2013-12-30

    申请人： The University of Kansas ,  CONOCOPHILLIPS COMPANY

    发明人： Huili GUAN ,  Cory BERKLAND ,  Ahmad MORADI-ARAGHI ,  Jenn-Tai LIANG ,  Terry M. CHRISTIAN ,  Riley B. Needham ,  Min CHENG ,  Faye Lynn SCULLY ,  James H. HEDGES

    IPC分类号： C09K8/588

    CPC分类号： C09K8/588 ,  C08L1/286 ,  C08L5/00

    摘要： The instant application relates to nanogels or compositions that hold multivalent metal ions until some level of nanogel degradation has occurred, then slowly release the multivalent metal ions for gelation with carboxylate containing polymers. Compositions comprising such nanogels, together with polymers that can be crosslinked with multivalent metal ions, allow the deployment of such mixtures in various applications, and greatly increased gelation times.

    摘要翻译： 本申请涉及保持多价金属离子直到发生一定程度的纳米凝胶降解的纳米凝胶或组合物，然后用含羧酸酯的聚合物缓慢释放多价金属离子用于凝胶化。 包含这些纳米凝胶的组合物以及可与多价金属离子交联的聚合物允许在各种应用中部署这些混合物，并大大增加凝胶化时间。

    Graphene oxide-based nanolab and methods of detecting of exosomes
    64.
    发明授权
    Graphene oxide-based nanolab and methods of detecting of exosomes 有权

    公开(公告)号：US10788486B2

    公开(公告)日：2020-09-29

    申请号：US15728155

    申请日：2017-10-09

    申请人： The University of Kansas ,  Kansas State University Research Foundation

    发明人： Peng Zhang ,  Yong Zeng ,  Mei He

    IPC分类号： G01N33/543 ,  B01L3/00 ,  G01N33/68

    摘要： A capture device for capturing a biological substance can include: a substrate; a graphene-oxide layer on the substrate; at least one polydopamine polymer coupled with the graphene-oxide; and at least one targeting receptor coupled to the polydopamine(s), wherein the targeting receptor is capable of targeting/binding with a target biological substance. The graphene-oxide may be covalently coupled with the substrate and polydopamine, and the polydopamine may be covalently coupled with the targeting receptor. The targeting receptor can be an antibody or fragment thereof. The target biological substance can be an exosome. The substrate can be a particle (e.g., magnetic, such as magnetically responsive) or a surface in a microfluidic channel. The surface can be a top surface of a post, the post having a Y-shaped cross-sectional profile. In one aspect, the substrate is a particle. The capture device can include the target biological substance bound to the targeting receptor.

    Methacrylated devitalized cartilage and devitalized cartilage particles
    66.
    发明授权
    Methacrylated devitalized cartilage and devitalized cartilage particles 有权

    公开(公告)号：US10744228B2

    公开(公告)日：2020-08-18

    申请号：US15254709

    申请日：2016-09-01

    申请人： The University of Kansas

    发明人： Michael Detamore ,  Emily Beck

    IPC分类号： A61L27/36 ,  A61L27/52 ,  A61L27/54 ,  A61L27/48

    摘要： An implantable composition can include methacrylated solubilized devitalized cartilage (MeSDVC) with or without devitalized cartilage (DVC) particles. These compositions can be hydrogel precursors. After implantation, the MeSDVC may be crosslinked so as to form a hydrogel. The crosslinked hydrogel can include the DVC particles. A hydrogel precursor matrix (e.g., not crosslinked) can include a crosslinkable substance that can be crosslinked into a hydrogel, where DVC particles are included in the precursor matrix. The hydrogel precursor matrix can be located in a tissue defect site, such as a hole or recess in a cartilage or bone, and then crosslinked into a hydrogel that has the DVC particles therein.

    Toll-like receptor agonists
    68.
    发明授权
    Toll-like receptor agonists 有权

    公开(公告)号：US10471139B2

    公开(公告)日：2019-11-12

    申请号：US14909967

    申请日：2014-08-15

    申请人： The University of Kansas

    发明人： Sunil Abraham David ,  Euna Yoo ,  Nikunj Shukla ,  Alex Christopher Salyer ,  Mallesh Beesu ,  Subbalakshmi S. Malladi ,  Cassandra Jones

    IPC分类号： C07D471/04 ,  A61K39/39 ,  C07D235/30 ,  A61K39/00

    摘要： Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.